SAN JUAN CAPISTRANO, Calif., July 26, 2007 (PRIME NEWSWIRE) -- American Mold Guard, Inc. (Nasdaq:AMGI), an industry leader in the field of antimicrobial surface treatment services, announced today through its wholly owned subsidiary, AMG Scientific, LLC, that it is funding a study at Rush University Medical Center in Chicago aimed at controlling hospital-acquired infections.
The two-phase study will test the impact of AMG Scientific's antimicrobial application on environmental bacterial contamination in intensive care patient rooms. The initial phase of the study is expected to begin in August 2007.
"We are honored to be chosen by Rush University Medical Center and to be working with their distinguished team of physicians. We believe that our surface infection control services will contribute significantly to the overall reduction of hospital-acquired infections," said Dr. Atif Malik, Chief Science Officer for AMG Scientific. "This study should help demonstrate the effectiveness of AMG Scientific's infection control service program in the reduction of harmful pathogens that are currently responsible for approximately 100,000 deaths annually in hospitals across the country," concluded Dr. Malik.
"We anticipate that a successful outcome from the completion of these studies will provide the scientific basis needed to market our infection control service to major facilities across the country," said Robert Bayer, Corporate Vice President of Sales for AMG Scientific.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans and projections regarding the company's financial position, results of operations, market position, product and service development and market strategy. These statements may be identified by the fact that they use words or phrases such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "will likely result," "will continue," "may," "could" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, competitive product and service development, the ability to fully develop the company's surface infection control services, future broad market acceptance of antimicrobial surface treatment services, difficulties in raising additional capital in the future, difficulties and delays in establishing the "Mold Guard" brand, the impact of the absence of significant proprietary technology underlying our services, changes in the anticipated size or trends of the markets in which we compete, judicial decisions and governmental laws and regulations, and changes in general economic conditions in the markets in which we may compete. For further details and a discussion of these and other risks and uncertainties, see our periodic reports including current reports on Form 8-K, quarterly reports on Form 10-QSB and our annual report on Form 10-KSB, furnished to and filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
About Rush University Medical Center Rush University Medical Center is an academic medical center that encompasses a 613-bed hospital serving adults and children, the 61-bed Johnston R. Bowman Health Center and Rush University. Rush University is home to one of the first medical colleges in the Midwest and one of the nation's top-ranked nursing colleges, as well as graduate programs in allied health, health systems management and biomedical research. The Medical Center also offers more than 70 highly selective residency and fellowship programs in medical and surgical specialties and subspecialties.
About American Mold Guard and AMG Scientific, LLC
American Mold Guard, Inc. (Nasdaq:AMGI), founded in 2002, is the industry leader in the field of antimicrobial surface treatment services. AMG Scientific, LLC is a wholly owned subsidiary of AMGI. Established in October 2006, AMG Scientific, LLC is focused on providing long-term antimicrobial infection control services to health care facilities and large institutions in an effort to provide an additional intervention safety net in the fight against hospital-acquired infections. Visit: www.amgscientific.com or www.americanmoldguard.com